Jazz Pharmaceuticals plc (JAZZ) Stock Competitors & Peer Comparison

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, VRTX has a market cap of 118.5B. Regarding current trading prices, JAZZ is priced at $226.09, while VRTX trades at $467.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas VRTX's P/E ratio is 27.70. In terms of profitability, JAZZ's ROE is +0.01%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, JAZZ is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check VRTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, JAZZ is priced at $226.09, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas VRNA's P/E ratio is -102.80. In terms of profitability, JAZZ's ROE is +0.01%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, JAZZ is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check VRNA's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, REGN has a market cap of 63.1B. Regarding current trading prices, JAZZ is priced at $226.09, while REGN trades at $619.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas REGN's P/E ratio is 14.96. In terms of profitability, JAZZ's ROE is +0.01%, compared to REGN's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check REGN's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ARGX has a market cap of 55.9B. Regarding current trading prices, JAZZ is priced at $226.09, while ARGX trades at $923.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ARGX's P/E ratio is 40.22. In terms of profitability, JAZZ's ROE is +0.01%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, JAZZ is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check ARGX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, JAZZ is priced at $226.09, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas SGEN's P/E ratio is -57.19. In terms of profitability, JAZZ's ROE is +0.01%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, JAZZ is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check SGEN's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ALNY has a market cap of 38.2B. Regarding current trading prices, JAZZ is priced at $226.09, while ALNY trades at $287.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ALNY's P/E ratio is 71.96. In terms of profitability, JAZZ's ROE is +0.01%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, JAZZ is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ALNY's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RVMDW has a market cap of 35.8B. Regarding current trading prices, JAZZ is priced at $226.09, while RVMDW trades at $7.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RVMDW's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.01%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, JAZZ is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check RVMDW's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RVMD has a market cap of 35.3B. Regarding current trading prices, JAZZ is priced at $226.09, while RVMD trades at $170.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RVMD's P/E ratio is -23.32. In terms of profitability, JAZZ's ROE is +0.01%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, JAZZ is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check RVMD's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, MRNA has a market cap of 23.5B. Regarding current trading prices, JAZZ is priced at $226.09, while MRNA trades at $63.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas MRNA's P/E ratio is -7.29. In terms of profitability, JAZZ's ROE is +0.01%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, JAZZ is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check MRNA's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RPRX has a market cap of 23B. Regarding current trading prices, JAZZ is priced at $226.09, while RPRX trades at $54.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RPRX's P/E ratio is 28.19. In terms of profitability, JAZZ's ROE is +0.01%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, JAZZ is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check RPRX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, JAZZ is priced at $226.09, while UTHR trades at $544.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas UTHR's P/E ratio is 19.91. In terms of profitability, JAZZ's ROE is +0.01%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, JAZZ is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check UTHR's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, BNTX has a market cap of 22.8B. Regarding current trading prices, JAZZ is priced at $226.09, while BNTX trades at $91.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas BNTX's P/E ratio is -15.31. In terms of profitability, JAZZ's ROE is +0.01%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, JAZZ is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check BNTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ROIV has a market cap of 22.5B. Regarding current trading prices, JAZZ is priced at $226.09, while ROIV trades at $31.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ROIV's P/E ratio is -57.87. In terms of profitability, JAZZ's ROE is +0.01%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, JAZZ is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ROIV's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, INSM has a market cap of 20.8B. Regarding current trading prices, JAZZ is priced at $226.09, while INSM trades at $99.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas INSM's P/E ratio is -16.63. In terms of profitability, JAZZ's ROE is +0.01%, compared to INSM's ROE of -1.30%. Regarding short-term risk, JAZZ is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check INSM's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, JAZZ is priced at $226.09, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas BGNE's P/E ratio is -22.55. In terms of profitability, JAZZ's ROE is +0.01%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, JAZZ is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check BGNE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, INCY has a market cap of 19.6B. Regarding current trading prices, JAZZ is priced at $226.09, while INCY trades at $104.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas INCY's P/E ratio is 13.87. In terms of profitability, JAZZ's ROE is +0.01%, compared to INCY's ROE of +0.29%. Regarding short-term risk, JAZZ is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check INCY's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, JAZZ is priced at $226.09, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.01%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, JAZZ is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check DNA-WT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, NBIX has a market cap of 16.3B. Regarding current trading prices, JAZZ is priced at $226.09, while NBIX trades at $162.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas NBIX's P/E ratio is 24.83. In terms of profitability, JAZZ's ROE is +0.01%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, JAZZ is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check NBIX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, GMAB has a market cap of 15.7B. Regarding current trading prices, JAZZ is priced at $226.09, while GMAB trades at $26.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas GMAB's P/E ratio is 19.55. In terms of profitability, JAZZ's ROE is +0.01%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, JAZZ is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check GMAB's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, JAZZ is priced at $226.09, while ASND trades at $235.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ASND's P/E ratio is 25.97. In terms of profitability, JAZZ's ROE is +0.01%, compared to ASND's ROE of -56.42%. Regarding short-term risk, JAZZ is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ASND's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, BBIO has a market cap of 13.5B. Regarding current trading prices, JAZZ is priced at $226.09, while BBIO trades at $69.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas BBIO's P/E ratio is -18.42. In terms of profitability, JAZZ's ROE is +0.01%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, JAZZ is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check BBIO's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, JAZZ is priced at $226.09, while EXEL trades at $51.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas EXEL's P/E ratio is 17.00. In terms of profitability, JAZZ's ROE is +0.01%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, JAZZ is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check EXEL's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, AXSM has a market cap of 12.8B. Regarding current trading prices, JAZZ is priced at $226.09, while AXSM trades at $249.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas AXSM's P/E ratio is -66.45. In terms of profitability, JAZZ's ROE is +0.01%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, JAZZ is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check AXSM's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, JAZZ is priced at $226.09, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas KRTX's P/E ratio is -28.09. In terms of profitability, JAZZ's ROE is +0.01%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, JAZZ is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check KRTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, JAZZ is priced at $226.09, while IONS trades at $76.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas IONS's P/E ratio is -36.88. In terms of profitability, JAZZ's ROE is +0.01%, compared to IONS's ROE of -0.59%. Regarding short-term risk, JAZZ is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check IONS's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, JAZZ is priced at $226.09, while MDGL trades at $514.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas MDGL's P/E ratio is -37.99. In terms of profitability, JAZZ's ROE is +0.01%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, JAZZ is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check MDGL's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ARWR has a market cap of 11.6B. Regarding current trading prices, JAZZ is priced at $226.09, while ARWR trades at $81.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ARWR's P/E ratio is -36.12. In terms of profitability, JAZZ's ROE is +0.01%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, JAZZ is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ARWR's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, JAZZ is priced at $226.09, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RNAM's P/E ratio is -17.39. In terms of profitability, JAZZ's ROE is +0.01%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, JAZZ is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check RNAM's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, SMMT has a market cap of 11.1B. Regarding current trading prices, JAZZ is priced at $226.09, while SMMT trades at $14.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas SMMT's P/E ratio is -8.98. In terms of profitability, JAZZ's ROE is +0.01%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, JAZZ is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check SMMT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, JAZZ is priced at $226.09, while BMRN trades at $56.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas BMRN's P/E ratio is 40.22. In terms of profitability, JAZZ's ROE is +0.01%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, JAZZ is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check BMRN's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, JAZZ is priced at $226.09, while KRYS trades at $343.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas KRYS's P/E ratio is 45.91. In terms of profitability, JAZZ's ROE is +0.01%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, JAZZ is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check KRYS's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CYTK has a market cap of 9.9B. Regarding current trading prices, JAZZ is priced at $226.09, while CYTK trades at $79.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CYTK's P/E ratio is -11.54. In terms of profitability, JAZZ's ROE is +0.01%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, JAZZ is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check CYTK's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, JAZZ is priced at $226.09, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RXDX's P/E ratio is -56.47. In terms of profitability, JAZZ's ROE is +0.01%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, JAZZ is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check RXDX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, JAZZ is priced at $226.09, while NUVL trades at $123.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas NUVL's P/E ratio is -20.37. In terms of profitability, JAZZ's ROE is +0.01%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, JAZZ is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check NUVL's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, JAZZ is priced at $226.09, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas IMGN's P/E ratio is -111.55. In terms of profitability, JAZZ's ROE is +0.01%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, JAZZ is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check IMGN's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, TECH has a market cap of 8.7B. Regarding current trading prices, JAZZ is priced at $226.09, while TECH trades at $56.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas TECH's P/E ratio is 79.44. In terms of profitability, JAZZ's ROE is +0.01%, compared to TECH's ROE of +0.05%. Regarding short-term risk, JAZZ is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check TECH's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CORT has a market cap of 8.6B. Regarding current trading prices, JAZZ is priced at $226.09, while CORT trades at $81.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CORT's P/E ratio is 227.74. In terms of profitability, JAZZ's ROE is +0.01%, compared to CORT's ROE of +0.08%. Regarding short-term risk, JAZZ is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check CORT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, JAZZ is priced at $226.09, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas BPMC's P/E ratio is -51.58. In terms of profitability, JAZZ's ROE is +0.01%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, JAZZ is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check BPMC's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, JAZZ is priced at $226.09, while TGTX trades at $54.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas TGTX's P/E ratio is 19.02. In terms of profitability, JAZZ's ROE is +0.01%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, JAZZ is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check TGTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, JAZZ is priced at $226.09, while APGE trades at $132.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas APGE's P/E ratio is -30.61. In terms of profitability, JAZZ's ROE is +0.01%, compared to APGE's ROE of -0.33%. Regarding short-term risk, JAZZ is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check APGE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, JAZZ is priced at $226.09, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CERE's P/E ratio is -16.47. In terms of profitability, JAZZ's ROE is +0.01%, compared to CERE's ROE of -0.72%. Regarding short-term risk, JAZZ is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check CERE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, JAZZ is priced at $226.09, while HALO trades at $69.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas HALO's P/E ratio is 24.21. In terms of profitability, JAZZ's ROE is +0.01%, compared to HALO's ROE of +1.26%. Regarding short-term risk, JAZZ is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check HALO's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, KYMR has a market cap of 8.2B. Regarding current trading prices, JAZZ is priced at $226.09, while KYMR trades at $99.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas KYMR's P/E ratio is -27.78. In terms of profitability, JAZZ's ROE is +0.01%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, JAZZ is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check KYMR's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, JAZZ is priced at $226.09, while ALKS trades at $46.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ALKS's P/E ratio is 51.13. In terms of profitability, JAZZ's ROE is +0.01%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, JAZZ is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ALKS's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, JAZZ is priced at $226.09, while IBRX trades at $7.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas IBRX's P/E ratio is -8.49. In terms of profitability, JAZZ's ROE is +0.01%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, JAZZ is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check IBRX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, PCVX has a market cap of 7.5B. Regarding current trading prices, JAZZ is priced at $226.09, while PCVX trades at $52.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas PCVX's P/E ratio is -7.56. In terms of profitability, JAZZ's ROE is +0.01%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, JAZZ is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check PCVX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, JAZZ is priced at $226.09, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas MTSR's P/E ratio is -23.58. In terms of profitability, JAZZ's ROE is +0.01%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, JAZZ is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check MTSR's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, PTGX has a market cap of 7.4B. Regarding current trading prices, JAZZ is priced at $226.09, while PTGX trades at $119.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas PTGX's P/E ratio is -63.55. In terms of profitability, JAZZ's ROE is +0.01%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, JAZZ is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check PTGX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, IMVT has a market cap of 7.3B. Regarding current trading prices, JAZZ is priced at $226.09, while IMVT trades at $38.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas IMVT's P/E ratio is -12.76. In terms of profitability, JAZZ's ROE is +0.01%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, JAZZ is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check IMVT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, JAZZ is priced at $226.09, while RYTM trades at $105.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RYTM's P/E ratio is -32.39. In terms of profitability, JAZZ's ROE is +0.01%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, JAZZ is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check RYTM's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, JAZZ is priced at $226.09, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas MRUS's P/E ratio is -17.05. In terms of profitability, JAZZ's ROE is +0.01%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, JAZZ is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check MRUS's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $226.09, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ACLX's P/E ratio is -28.27. In terms of profitability, JAZZ's ROE is +0.01%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, JAZZ is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check ACLX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, PTCT has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $226.09, while PTCT trades at $82.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas PTCT's P/E ratio is -31.87. In terms of profitability, JAZZ's ROE is +0.01%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, JAZZ is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check PTCT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, LQDA has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $226.09, while LQDA trades at $76.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas LQDA's P/E ratio is 444.06. In terms of profitability, JAZZ's ROE is +0.01%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, JAZZ is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check LQDA's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $226.09, while ABVX trades at $99.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ABVX's P/E ratio is -19.00. In terms of profitability, JAZZ's ROE is +0.01%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, JAZZ is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ABVX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, JAZZ is priced at $226.09, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RETA's P/E ratio is -66.29. In terms of profitability, JAZZ's ROE is +0.01%, compared to RETA's ROE of +0.47%. Regarding short-term risk, JAZZ is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check RETA's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, PRAX has a market cap of 6.4B. Regarding current trading prices, JAZZ is priced at $226.09, while PRAX trades at $305.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas PRAX's P/E ratio is -22.60. In terms of profitability, JAZZ's ROE is +0.01%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, JAZZ is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check PRAX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, JAZZ is priced at $226.09, while CNTA trades at $40.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CNTA's P/E ratio is -22.57. In terms of profitability, JAZZ's ROE is +0.01%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, JAZZ is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check CNTA's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, COGT has a market cap of 6.1B. Regarding current trading prices, JAZZ is priced at $226.09, while COGT trades at $35.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas COGT's P/E ratio is -16.52. In terms of profitability, JAZZ's ROE is +0.01%, compared to COGT's ROE of -0.83%. Regarding short-term risk, JAZZ is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check COGT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, SYRE has a market cap of 6.1B. Regarding current trading prices, JAZZ is priced at $226.09, while SYRE trades at $101.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas SYRE's P/E ratio is -47.32. In terms of profitability, JAZZ's ROE is +0.01%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, JAZZ is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check SYRE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, JAZZ is priced at $226.09, while BLTE trades at $146.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas BLTE's P/E ratio is -57.90. In terms of profitability, JAZZ's ROE is +0.01%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, JAZZ is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check BLTE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, JAZZ is priced at $226.09, while SRRK trades at $51.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas SRRK's P/E ratio is -14.22. In terms of profitability, JAZZ's ROE is +0.01%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, JAZZ is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check SRRK's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CGON has a market cap of 5.8B. Regarding current trading prices, JAZZ is priced at $226.09, while CGON trades at $65.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CGON's P/E ratio is -28.31. In terms of profitability, JAZZ's ROE is +0.01%, compared to CGON's ROE of -0.23%. Regarding short-term risk, JAZZ is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check CGON's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, JAZZ is priced at $226.09, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CDTX's P/E ratio is -19.77. In terms of profitability, JAZZ's ROE is +0.01%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, JAZZ is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check CDTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $226.09, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, JAZZ's ROE is +0.01%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, JAZZ is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check ABCM's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $226.09, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ISEE's P/E ratio is -22.44. In terms of profitability, JAZZ's ROE is +0.01%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, JAZZ is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check ISEE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, JAZZ is priced at $226.09, while LEGN trades at $29.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas LEGN's P/E ratio is -21.26. In terms of profitability, JAZZ's ROE is +0.01%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, JAZZ is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check LEGN's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, JAZZ is priced at $226.09, while MIRM trades at $108.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas MIRM's P/E ratio is -7.91. In terms of profitability, JAZZ's ROE is +0.01%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, JAZZ is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check MIRM's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, JAZZ is priced at $226.09, while FBIOX trades at $26.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas FBIOX's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.01%, compared to FBIOX's ROE of N/A. Regarding short-term risk, JAZZ is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check FBIOX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, LGND has a market cap of 5.3B. Regarding current trading prices, JAZZ is priced at $226.09, while LGND trades at $268.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas LGND's P/E ratio is 34.05. In terms of profitability, JAZZ's ROE is +0.01%, compared to LGND's ROE of +0.16%. Regarding short-term risk, JAZZ is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check LGND's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, JAZZ is priced at $226.09, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas APLS's P/E ratio is 38.35. In terms of profitability, JAZZ's ROE is +0.01%, compared to APLS's ROE of +0.40%. Regarding short-term risk, JAZZ is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check APLS's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, JAZZ is priced at $226.09, while CRSP trades at $55.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CRSP's P/E ratio is -8.81. In terms of profitability, JAZZ's ROE is +0.01%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, JAZZ is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check CRSP's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, TVTX has a market cap of 5.1B. Regarding current trading prices, JAZZ is priced at $226.09, while TVTX trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas TVTX's P/E ratio is -110.22. In terms of profitability, JAZZ's ROE is +0.01%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, JAZZ is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check TVTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, JAZZ is priced at $226.09, while CAI trades at $17.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CAI's P/E ratio is -6.27. In terms of profitability, JAZZ's ROE is +0.01%, compared to CAI's ROE of +0.06%. Regarding short-term risk, JAZZ is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check CAI's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, JAZZ is priced at $226.09, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas TERN's P/E ratio is -51.41. In terms of profitability, JAZZ's ROE is +0.01%, compared to TERN's ROE of -0.20%. Regarding short-term risk, JAZZ is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check TERN's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, JAZZ is priced at $226.09, while ERAS trades at $15.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ERAS's P/E ratio is -16.22. In terms of profitability, JAZZ's ROE is +0.01%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, JAZZ is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ERAS's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $226.09, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas FOLD's P/E ratio is -161.00. In terms of profitability, JAZZ's ROE is +0.01%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, JAZZ is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check FOLD's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $226.09, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas AKRO's P/E ratio is -14.57. In terms of profitability, JAZZ's ROE is +0.01%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, JAZZ is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check AKRO's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $226.09, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ALPN's P/E ratio is -101.52. In terms of profitability, JAZZ's ROE is +0.01%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, JAZZ is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check ALPN's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, JAZZ is priced at $226.09, while CELC trades at $90.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CELC's P/E ratio is -23.06. In terms of profitability, JAZZ's ROE is +0.01%, compared to CELC's ROE of -2.45%. Regarding short-term risk, JAZZ is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check CELC's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, JAZZ is priced at $226.09, while XENE trades at $54.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas XENE's P/E ratio is -11.66. In terms of profitability, JAZZ's ROE is +0.01%, compared to XENE's ROE of -0.49%. Regarding short-term risk, JAZZ is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check XENE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, KNSA has a market cap of 4.3B. Regarding current trading prices, JAZZ is priced at $226.09, while KNSA trades at $58.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas KNSA's P/E ratio is 62.78. In terms of profitability, JAZZ's ROE is +0.01%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, JAZZ is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check KNSA's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, JAZZ is priced at $226.09, while MANE trades at $104.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas MANE's P/E ratio is -38.78. In terms of profitability, JAZZ's ROE is +0.01%, compared to MANE's ROE of -0.95%. Regarding short-term risk, JAZZ is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check MANE's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, VCYT has a market cap of 4.2B. Regarding current trading prices, JAZZ is priced at $226.09, while VCYT trades at $53.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas VCYT's P/E ratio is 49.25. In terms of profitability, JAZZ's ROE is +0.01%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, JAZZ is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check VCYT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, JAZZ is priced at $226.09, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas OPT's P/E ratio is -1.52. In terms of profitability, JAZZ's ROE is +0.01%, compared to OPT's ROE of +1.09%. Regarding short-term risk, JAZZ is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check OPT's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, JAZZ is priced at $226.09, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas MRTX's P/E ratio is -4.82. In terms of profitability, JAZZ's ROE is +0.01%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, JAZZ is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check MRTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, DFTX has a market cap of 4B. Regarding current trading prices, JAZZ is priced at $226.09, while DFTX trades at $38.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas DFTX's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.01%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, JAZZ is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check DFTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, EWTX has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $226.09, while EWTX trades at $38.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas EWTX's P/E ratio is -21.99. In terms of profitability, JAZZ's ROE is +0.01%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, JAZZ is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check EWTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, JAZZ is priced at $226.09, while CPRX trades at $31.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CPRX's P/E ratio is 18.14. In terms of profitability, JAZZ's ROE is +0.01%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, JAZZ is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check CPRX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, JAZZ is priced at $226.09, while DNLI trades at $24.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas DNLI's P/E ratio is -8.35. In terms of profitability, JAZZ's ROE is +0.01%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, JAZZ is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check DNLI's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, JAZZ is priced at $226.09, while ACAD trades at $22.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas ACAD's P/E ratio is 10.00. In terms of profitability, JAZZ's ROE is +0.01%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, JAZZ is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check ACAD's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, JAZZ is priced at $226.09, while VKTX trades at $34.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas VKTX's P/E ratio is -7.80. In terms of profitability, JAZZ's ROE is +0.01%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, JAZZ is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check VKTX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, JAZZ is priced at $226.09, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas RYZB's P/E ratio is -57.86. In terms of profitability, JAZZ's ROE is +0.01%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, JAZZ is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check RYZB's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, JAZZ is priced at $226.09, while CRNX trades at $36.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CRNX's P/E ratio is -6.88. In terms of profitability, JAZZ's ROE is +0.01%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, JAZZ is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check CRNX's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, JAZZ is priced at $226.09, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas CBAY's P/E ratio is -32.81. In terms of profitability, JAZZ's ROE is +0.01%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, JAZZ is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for JAZZ.Check CBAY's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, BEAM has a market cap of 3.7B. Regarding current trading prices, JAZZ is priced at $226.09, while BEAM trades at $35.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas BEAM's P/E ratio is -72.51. In terms of profitability, JAZZ's ROE is +0.01%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, JAZZ is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check BEAM's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, JAZZ is priced at $226.09, while DNTH trades at $88.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas DNTH's P/E ratio is -20.65. In terms of profitability, JAZZ's ROE is +0.01%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, JAZZ is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check DNTH's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, JAZZ is priced at $226.09, while NAMS trades at $30.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas NAMS's P/E ratio is -17.31. In terms of profitability, JAZZ's ROE is +0.01%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, JAZZ is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check NAMS's competition here

JAZZ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.1B. In comparison, TNGX has a market cap of 3.5B. Regarding current trading prices, JAZZ is priced at $226.09, while TNGX trades at $28.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 2042.36, whereas TNGX's P/E ratio is -34.34. In terms of profitability, JAZZ's ROE is +0.01%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, JAZZ is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for JAZZ.Check TNGX's competition here